Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials
Open Access
- 30 September 2009
- journal article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 10 (9), 872-876
- https://doi.org/10.1016/s1470-2045(09)70201-3
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Adjuvant bisphosphonates in breast cancer: Are we witnessing the emergence of a new therapeutic strategy?European Journal of Cancer, 2009
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerThe New England Journal of Medicine, 2009
- Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi‐arm, multistage randomized controlled trialBJU International, 2009
- STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer — A Multi-Arm Multi-Stage Randomised Controlled TrialClinical Oncology, 2008
- Exploring the anti-tumour activity of bisphosphonates in early breast cancerCancer Treatment Reviews, 2008
- New research findings on zoledronic acid: Survival, pain, and anti-tumour effectsCancer Treatment Reviews, 2008
- Oral Sodium Clodronate for Nonmetastatic Prostate Cancer--Results of a Randomized Double-Blind Placebo-Controlled Trial: Medical Research Council PR04 (ISRCTN61384873)JNCI Journal of the National Cancer Institute, 2007
- The role of bisphosphonates in breast and prostate cancers.Endocrine-Related Cancer, 2004
- Osteoprotegerin inhibits prostate cancer–induced osteoclastogenesis and prevents prostate tumor growth in the boneJCI Insight, 2001
- Generalised Increase in Bone Resorption in Carcinoma of the ProstateBJU International, 1985